Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Anyone see the acquisition rumors?
Takeover news hits NWBO and RXII
http://finance.sfgate.com/hearst.sfgate/news/read?GUID=13402870
More Mergers and Acquisitions Coming to Biotech Sector
While the biotech sector upswing has slowed given the recent fears on Wall Street, mergers and acquisitions in the sector should be more active this summer as larger companies look to acquire specific technologies or revenue and because many smaller companies do not have ready access to enough capital from retail investors to survive.
Two areas expected to see some M&A activity soon include experimental therapeutics based on RNA interference (RNAi) and novel therapeutics that harness the immune system to fight cancer.
Both of these platforms represent a promising new class of very profitable drugs for the targeted treatment of diseases including cancer and cardiovascular disease.
One of the greatest challenges for the pharmaceutical industry has in developing RNAi-based therapeutics has been finding ways to deliver them to their target while keeping them fully active. One company which has been attracting interest from some of the major pharmaceutical players is RXi Pharmaceuticals Corporation (Nasdaq: RXII). RXi's proprietary sd-rxRNA molecules, which have unique properties of 'self delivery' seem to be the focus of the interest. Earlier in the year, the company was rumored to be close to a deal, but walked away from talks after raising money. The stock tanked on fears of dilution, but in recent days, shares in the company have begun to rise on new speculation that news about a partnership may be close once again.
Another small company with a big target on their back at the moment is Northwest Biotherapeutics (OTC BB: NWBO.OB). Shares in the company have both risen and dropped in recent weeks as both whispers and published reports- including one by Louis Basenese of MoneyWeek, who put the company on his shortlist of takeover targets in this area.
Pharmaceutical industry leaders and investors appear to be actively looking for the next personalized medicine breakthrough given Dendreon Corporation's (NASDAQ: DNDN) price appreciation from the announcement of their FDA approved Provenge immunotherapy treatment for prostate cancer.
Two days ago, after a detailed report authored by renowned research pharma analyst Dr. Navid Malik got the attention of many in the pharmaceutical industry. Several companies have placed calls inquiring about Northwest Biotherapeutics' vaccine to combat brain cancer, DCVax after his 40 page report from London extensively praised the personalized vaccine and its recent clinical trial results data.
Malik goes on record to say that in addition to the competitive advantage which Northwest Biotherapeutics derives from this data, the manufacturing process developed by the company and the economies of scale delivered by their patented processes further places NWBO in a very competitive position in comparison with the product offered by Dendreon.
NWBO has also been attracting more attention from institutional investors in recent weeks. Company officials have been attempting to clean up their books and are said to be preparing for more meetings in front of hedge funds and money managers in the coming days. This could be a signal to some speculators that some positive activity is expected in the stock.
NWBO breaking out on takeover news:
http://finance.sfgate.com/hearst.sfgate/news/read?GUID=13402870
More Mergers and Acquisitions Coming to Biotech Sector
Thursday, 10 June 2010
While the biotech sector upswing has slowed given the recent fears on Wall Street, mergers and acquisitions in the sector should be more active this summer as larger companies look to acquire specific technologies or revenue and because many smaller companies do not have ready access to enough capital from retail investors to survive.
Two areas expected to see some M&A activity soon include experimental therapeutics based on RNA interference (RNAi) and novel therapeutics that harness the immune system to fight cancer.
Both of these platforms represent a promising new class of very profitable drugs for the targeted treatment of diseases including cancer and cardiovascular disease.
One of the greatest challenges for the pharmaceutical industry has in developing RNAi-based therapeutics has been finding ways to deliver them to their target while keeping them fully active. One company which has been attracting interest from some of the major pharmaceutical players is RXi Pharmaceuticals Corporation (Nasdaq: RXII). RXi's proprietary sd-rxRNA molecules, which have unique properties of 'self delivery' seem to be the focus of the interest. Earlier in the year, the company was rumored to be close to a deal, but walked away from talks after raising money. The stock tanked on fears of dilution, but in recent days, shares in the company have begun to rise on new speculation that news about a partnership may be close once again.
Another small company with a big target on their back at the moment is Northwest Biotherapeutics (OTC BB: NWBO.OB). Shares in the company have both risen and dropped in recent weeks as both whispers and published reports- including one by Louis Basenese of MoneyWeek, who put the company on his shortlist of takeover targets in this area.
Pharmaceutical industry leaders and investors appear to be actively looking for the next personalized medicine breakthrough given Dendreon Corporation's (NASDAQ: DNDN) price appreciation from the announcement of their FDA approved Provenge immunotherapy treatment for prostate cancer.
Two days ago, after a detailed report authored by renowned research pharma analyst Dr. Navid Malik got the attention of many in the pharmaceutical industry. Several companies have placed calls inquiring about Northwest Biotherapeutics' vaccine to combat brain cancer, DCVax after his 40 page report from London extensively praised the personalized vaccine and its recent clinical trial results data.
Malik goes on record to say that in addition to the competitive advantage which Northwest Biotherapeutics derives from this data, the manufacturing process developed by the company and the economies of scale delivered by their patented processes further places NWBO in a very competitive position in comparison with the product offered by Dendreon.
NWBO has also been attracting more attention from institutional investors in recent weeks. Company officials have been attempting to clean up their books and are said to be preparing for more meetings in front of hedge funds and money managers in the coming days. This could be a signal to some speculators that some positive activity is expected in the stock.
NWBO breaking out on takeover news:
http://finance.sfgate.com/hearst.sfgate/news/read?GUID=13402870
More Mergers and Acquisitions Coming to Biotech Sector
Thursday, 10 June 2010
While the biotech sector upswing has slowed given the recent fears on Wall Street, mergers and acquisitions in the sector should be more active this summer as larger companies look to acquire specific technologies or revenue and because many smaller companies do not have ready access to enough capital from retail investors to survive.
Two areas expected to see some M&A activity soon include experimental therapeutics based on RNA interference (RNAi) and novel therapeutics that harness the immune system to fight cancer.
Both of these platforms represent a promising new class of very profitable drugs for the targeted treatment of diseases including cancer and cardiovascular disease.
One of the greatest challenges for the pharmaceutical industry has in developing RNAi-based therapeutics has been finding ways to deliver them to their target while keeping them fully active. One company which has been attracting interest from some of the major pharmaceutical players is RXi Pharmaceuticals Corporation (Nasdaq: RXII). RXi's proprietary sd-rxRNA molecules, which have unique properties of 'self delivery' seem to be the focus of the interest. Earlier in the year, the company was rumored to be close to a deal, but walked away from talks after raising money. The stock tanked on fears of dilution, but in recent days, shares in the company have begun to rise on new speculation that news about a partnership may be close once again.
Another small company with a big target on their back at the moment is Northwest Biotherapeutics (OTC BB: NWBO.OB). Shares in the company have both risen and dropped in recent weeks as both whispers and published reports- including one by Louis Basenese of MoneyWeek, who put the company on his shortlist of takeover targets in this area.
Pharmaceutical industry leaders and investors appear to be actively looking for the next personalized medicine breakthrough given Dendreon Corporation's (NASDAQ: DNDN) price appreciation from the announcement of their FDA approved Provenge immunotherapy treatment for prostate cancer.
Two days ago, after a detailed report authored by renowned research pharma analyst Dr. Navid Malik got the attention of many in the pharmaceutical industry. Several companies have placed calls inquiring about Northwest Biotherapeutics' vaccine to combat brain cancer, DCVax after his 40 page report from London extensively praised the personalized vaccine and its recent clinical trial results data.
Malik goes on record to say that in addition to the competitive advantage which Northwest Biotherapeutics derives from this data, the manufacturing process developed by the company and the economies of scale delivered by their patented processes further places NWBO in a very competitive position in comparison with the product offered by Dendreon.
NWBO has also been attracting more attention from institutional investors in recent weeks. Company officials have been attempting to clean up their books and are said to be preparing for more meetings in front of hedge funds and money managers in the coming days. This could be a signal to some speculators that some positive activity is expected in the stock.
NWBO breaking out on takeover news:
http://finance.sfgate.com/hearst.sfgate/news/read?GUID=13402870
More Mergers and Acquisitions Coming to Biotech Sector
Thursday, 10 June 2010
While the biotech sector upswing has slowed given the recent fears on Wall Street, mergers and acquisitions in the sector should be more active this summer as larger companies look to acquire specific technologies or revenue and because many smaller companies do not have ready access to enough capital from retail investors to survive.
Two areas expected to see some M&A activity soon include experimental therapeutics based on RNA interference (RNAi) and novel therapeutics that harness the immune system to fight cancer.
Both of these platforms represent a promising new class of very profitable drugs for the targeted treatment of diseases including cancer and cardiovascular disease.
One of the greatest challenges for the pharmaceutical industry has in developing RNAi-based therapeutics has been finding ways to deliver them to their target while keeping them fully active. One company which has been attracting interest from some of the major pharmaceutical players is RXi Pharmaceuticals Corporation (Nasdaq: RXII). RXi's proprietary sd-rxRNA molecules, which have unique properties of 'self delivery' seem to be the focus of the interest. Earlier in the year, the company was rumored to be close to a deal, but walked away from talks after raising money. The stock tanked on fears of dilution, but in recent days, shares in the company have begun to rise on new speculation that news about a partnership may be close once again.
Another small company with a big target on their back at the moment is Northwest Biotherapeutics (OTC BB: NWBO.OB). Shares in the company have both risen and dropped in recent weeks as both whispers and published reports- including one by Louis Basenese of MoneyWeek, who put the company on his shortlist of takeover targets in this area.
Pharmaceutical industry leaders and investors appear to be actively looking for the next personalized medicine breakthrough given Dendreon Corporation's (NASDAQ: DNDN) price appreciation from the announcement of their FDA approved Provenge immunotherapy treatment for prostate cancer.
Two days ago, after a detailed report authored by renowned research pharma analyst Dr. Navid Malik got the attention of many in the pharmaceutical industry. Several companies have placed calls inquiring about Northwest Biotherapeutics' vaccine to combat brain cancer, DCVax after his 40 page report from London extensively praised the personalized vaccine and its recent clinical trial results data.
Malik goes on record to say that in addition to the competitive advantage which Northwest Biotherapeutics derives from this data, the manufacturing process developed by the company and the economies of scale delivered by their patented processes further places NWBO in a very competitive position in comparison with the product offered by Dendreon.
NWBO has also been attracting more attention from institutional investors in recent weeks. Company officials have been attempting to clean up their books and are said to be preparing for more meetings in front of hedge funds and money managers in the coming days. This could be a signal to some speculators that some positive activity is expected in the stock.
Looks like biomedreports got it right. again. Bashers suck while bulls make money!
Stock went nuts after biomedreports issued a trade alert tot heir subscribers late today. they say that big positive cancer news is coming. Should be an interesting day tomorrow.
POSC news conference announcement expected!
http://biomedreports.com/articles/most-popular/37131-update-posc-rumors.html
Following up on the rumors we have been chasing for two weeks, it appears that staffers at Positron Corporation (OTCBB:POSC) have been busy making arrangements for a soon to be announced press conference.
This news according to multiple sources who also told BioMedReports on Thursday that an official announcement about "a big development for the company" may be issued as early as Monday.
Yesterday, prices took a hit after a blogger made false and defamatory accusations against not only BioMedReports, but the company as well. This is the second time that the blogger has attacked BioMedReports's and owners of this website intend to take swift and complete legal action against the owner/author of that web site. Thus far, after multiple requests, the author of the website has refused to provide us with his legal contact information so that our legal department can commence those actions.
The fact remains that POSC is an established company that has been in business for over a quarter of a century and that a positive announcement- apparently worthy of a press conference- will be made public in the coming days. Speculation continues that a multi-billion dollar company trading on the NYSE at over $50 per share has taken an interest in the company.
Furthermore, sources at the company tell BioMedReports that pending orders for their FDA approved, Frost and Sullivan award winning imaging system run at least "over one hundred deep."
As we told subscribers two days ago, we fully expect the stock price to see substantial gains (beyond the initial 43% gains seen immediately after our trade alert) as it now appears that the company had positioned itself to be the clear leader in the five billion dollar molecular imaging market. Positron's PET (Positron Emission Tomography) scanner, known as the “Attrius”, has robust cardiac specific imaging software and, more importantly, is the only "PET" imaging device in the entire industry (see related story).
In a letter to shareholders last month, the chairman of the board for the company informed investors that "Positron has several immediate opportunities with some of the largest companies in the nuclear medicine industry. Any combination of success with these opportunities will have a tremendous positive present and future impact on Positron."
It is clear that a positive development worthy of a full press conference (rumored arrangements place it at the Nasdaq MarketSite in New York City) may be officially announced as early as Monday.
If true, naked shorters who took negative positions in the stock will not only have to cover, they will help push the stock price much higher by doing so.
Developing...
POSC news conference announcement expected by Monday!
http://biomedreports.com/articles/most-popular/37131-update-posc-rumors.html
Following up on the rumors we have been chasing for two weeks, it appears that staffers at Positron Corporation (OTCBB:POSC) have been busy making arrangements for a soon to be announced press conference.
This news according to multiple sources who also told BioMedReports on Thursday that an official announcement about "a big development for the company" may be issued as early as Monday.
Yesterday, prices took a hit after a blogger made false and defamatory accusations against not only BioMedReports, but the company as well. This is the second time that the blogger has attacked BioMedReports's and owners of this website intend to take swift and complete legal action against the owner/author of that web site. Thus far, after multiple requests, the author of the website has refused to provide us with his legal contact information so that our legal department can commence those actions.
The fact remains that POSC is an established company that has been in business for over a quarter of a century and that a positive announcement- apparently worthy of a press conference- will be made public in the coming days. Speculation continues that a multi-billion dollar company trading on the NYSE at over $50 per share has taken an interest in the company.
Furthermore, sources at the company tell BioMedReports that pending orders for their FDA approved, Frost and Sullivan award winning imaging system run at least "over one hundred deep."
As we told subscribers two days ago, we fully expect the stock price to see substantial gains (beyond the initial 43% gains seen immediately after our trade alert) as it now appears that the company had positioned itself to be the clear leader in the five billion dollar molecular imaging market. Positron's PET (Positron Emission Tomography) scanner, known as the “Attrius”, has robust cardiac specific imaging software and, more importantly, is the only "PET" imaging device in the entire industry (see related story).
In a letter to shareholders last month, the chairman of the board for the company informed investors that "Positron has several immediate opportunities with some of the largest companies in the nuclear medicine industry. Any combination of success with these opportunities will have a tremendous positive present and future impact on Positron."
It is clear that a positive development worthy of a full press conference (rumored arrangements place it at the Nasdaq MarketSite in New York City) may be officially announced as early as Monday.
If true, naked shorters who took negative positions in the stock will not only have to cover, they will help push the stock price much higher by doing so.
Developing...
This was Garza's call from BioMedReports. Huge call!
MCLN announces record financial results:
http://biomedreports.com/articles/most-popular/31198-medclean-releases-financial-report.html
Was this the NVLT article Dew was looking for?
Or is it the one in the "related articles" box?
http://biomedreports.com/articles/most-popular/30325-novelos-therapeutics-nvltob-what-now.html
MSBT flying on media coverage
Several sources talking about them. Green on a bad market day:
http://www.tradingmarkets.com/news/stock-alert/msbt_medasorb-s-blockbuster-product-could-be-commercialized-this-year-753686.html
They didn't say they would be adding 9 new hospitals. Chat capture below
Pumpers!
;)
Wait.. What happened to all the bashers who were in here saying this was just another (the latest) pump and dump?
You're welcome. Now spread the news! This thing is gonna fly!
HDVY story in today's San Francisco Chronicle!
This is really exciting. I think something big is happening here. Something much bigger than anyone thinks.
must read here:
http://finance.sfgate.com/hearst.sfgate/news/read?GUID=11728212
San Francisco Chronicle on HDVY!
Great article! Must read:
http://finance.sfgate.com/hearst.sfgate/news/read?GUID=11728212
No such link exists because they do not have any "bankrupt" companies on their FDA calendar. That happened also recently with another company that got FDA approval and when I wrote and asked them WTF happened, they said that they would never encourage an investment into a company involved in bankruptcy.
My hope is that after the HDVY news hits, people will see what a great company it is compared to VRML.PK and that is my whole point here.
Great post. Thanks for that info. See what I mean? Great company that i wouldn't have heard of otherwise before this big price move.
CBAI dilluted big time
I disagree. I think Biomedreports has provided a ton of great DD. I too am a subscriber and they have made me tons of money on DNDN, HGSI, NVLT, EXAS and many many others. Last week alone they alerted on NBS and IRBS, which are both winners long and short term and I had not really heard or payed attention to those companies before. Let's forget that those last two or three winners came on terrible market days.
Same now for HDVY. It was a roller coaster out there the last two or three days and HDVY has run!
I really like what I am hearing about this company and see that they are in the right place at the right time. I have friends who also follow biomed, but when someone claims that a "newsletter" brings 12 million shares in volume worth of attention to a stock, I have to pause and wonder if that is only them or if the bankers/institutionals that are tapped in to what is happening for HDVY.
Great looking chart. Looks like we're just entering the power zone here.
Great find. Thank you for posting those patent links! Nice DD!
They will be bigger than VRML. They have a test based on the same technology that can be used for the deadliest forms of cancer. That's a lot of royalties. The market for VRML's test is so small. That's a HYPE stock.
CNN says BioModa (OTCBB:BMOD) undervalued!
Biomoda Is an Undervalued Cancer Diagnostics Company With Important Pending Developments (OTCBB: BMOD)
http://money.cnn.com/news/newsfeeds/articles/marketwire/0581456.htm
Biomoda's Pending Developments Have Stock Rising
http://www.tradingmarkets.com/news/stock-alert/bmod_biomoda-s-pending-developments-have-stock-rising-732458.html
Great call on PARD!
Late day rumors launch IR Biosciences (OTC:IRBS)
Story:
http://biomedreports.com/articles/most-popular/25892-rxnews-recap-for-friday-01-22-10.html
Another great call. PARD's action was even mentioned on my trading screen by Dow Jones!
NWCI is clearly undervalued even at these levels. So what's the problem?
Great post! Thanks for sharing that. Obviously even if the guy is a penny pumper, he'll lose all credibility by sticking his neck out too far. The jury is still out on this one but even on the most red days, these guys have winners. They were the ones who alerted PARD today and it made news everywhere. Stock went crazy. Yesterday, they alerted on Hana Biosciences without a position and it also went nuts. Meanwhile, the rest of the market is red. What calls have you made lately Pianobench?
Great call on PARD. Huge Day!
IRBS up big and running on rumors at the end of the day. Good news coming. Insiders buying!
PARD starting to move on trade alert!
"This morning, we have confirmed that Poniard Pharmaceuticals' (NASDAQ:PARD) CEO and President will be presenting some important clinical data in the form of an abstract at this weekend's American Society of Clinical Oncology 2010 Gastrointestinal Cancers Symposium.
We are hearing that the data that will be presented on Sunday looks very strong and will likely re-new some interest in the company and their efforts to bring their ambitious multi-cancer drug platform through the regulatory process."
from biomed reports!
Is NBS going to dilute? Looks like good news is coming and they may use that to raise money:
Form Type: S-1/A
Filing Date: 1/19/2010
Description: Securities Registration Statement
http://www.sec.gov/Archives/edgar/data/320017/000114420410002327/v171551_s1a.htm